# AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

> **NCT00574951** · PHASE2 · TERMINATED · sponsor: **Gynecologic Oncology Group** · enrollment: 23 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** motesanib diphosphate

## Key facts

- **NCT ID:** NCT00574951
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2013-07
- **Final completion:** —
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Study was stopped for severe toxicity causing concern for patients
- **Last updated:** 2018-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574951, "AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00574951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*